Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Eligo Bioscience

Eligo Bioscience

Biotherapeautics company founded in 2014 and based in Paris that uses proprietary methods in synthetic biology, protein and genome engineering to produce Eligobiotics, products which intervene with the microbiome as diagnostics, antimicrobials and modulators of host-microbiome interactions.

Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in Paris and now resides at the Paris Biotech Santé at Cochin Hospital.

Eligo Bioscience develops Eligobiotics, which are nano-delivery vehicles that are based on non-replicative phage particles that are engineered and programmed to package synthetic genetic circuits.

In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”.

Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.


On July 9, 2015 Eligo Bioscience completed their seed funding round with €2.6M from Seventure Partners (lead investor) and Worldwide Innovation Challenge.

Series A

On September 26, 2017 Eligo Bioscience completed their series A funding round with $20million in funding from Seventure Partners and Khosla Ventures.


January 2019
Eligo Bioscience raises a $4,717,884 grant from EASME.
September 2017
Eligo Bioscience raises a $20,000,000 series A round from Khosla Ventures and Seventure Partners.
September 2017
Eligo Bioscience raises a $2,000,000 grant from Worldwide Innovation Challenge.
July 2015
Eligo Bioscience raises a $3,145,256 seed round from Seventure Partners and Worldwide Innovation Challenge.
Eligo Bioscience was founded by David Bikard, Luciano Marraffini, Timothy Lu and Xavier Duportet.

Funding Rounds


Further Resources



Eligo Bioscience SA
June 15, 2021
/PRNewswire/ -- Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its...
Eligo Bioscience
January 11, 2021
/PRNewswire/ -- Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at...


Golden logo
By using this site, you agree to our Terms & Conditions.